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Summary
Background Coronary artery calcium (CAC) score is a clinically validated marker of cardiovascular disease risk. We 
developed and validated a novel cardiovascular risk stratification system based on deep-learning-predicted CAC from 
retinal photographs.
Methods We used 216 152 retinal photographs from five datasets from South Korea, Singapore, and the UK to train 
and validate the algorithms. First, using one dataset from a South Korean health-screening centre, we trained a deep-
learning algorithm to predict the probability of the presence of CAC (ie, deep-learning retinal CAC score, RetiCAC). 
We stratified RetiCAC scores into tertiles and used Cox proportional hazards models to evaluate the ability of RetiCAC 
to predict cardiovascular events based on external test sets from South Korea, Singapore, and the UK Biobank. 
We evaluated the incremental values of RetiCAC when added to the Pooled Cohort Equation (PCE) for participants in 
the UK Biobank.
Findings RetiCAC outperformed all single clinical parameter models in predicting the presence of CAC (area under 
the receiver operating characteristic curve of 0∙742, 95% CI 0∙732–0∙753). Among the 527 participants in the 
South Korean clinical cohort, 33 (6∙3%) had cardiovascular events during the 5-year follow-up. When compared with 
the current CAC risk stratification (0, >0–100, and >100), the three-strata RetiCAC showed comparable prognostic 
performance with a concordance index of 0∙71. In the Singapore population-based cohort (n=8551), 
310 (3∙6%) participants had fatal cardiovascular events over 10 years, and the three-strata RetiCAC was significantly 
associated with increased risk of fatal cardiovascular events (hazard ratio [HR] trend 1∙33, 95% CI 1∙04–1∙71). In the 
UK Biobank (n=47 679), 337 (0∙7%) participants had fatal cardiovascular events over 10 years. When added to the PCE, 
the three-strata RetiCAC improved cardiovascular risk stratification in the intermediate-risk group (HR trend 1∙28, 
95% CI 1∙07–1∙54) and borderline-risk group (1∙62, 1∙04–2∙54), and the continuous net reclassification index 
was 0∙261 (95% CI 0∙124–0∙364).
Interpretation A deep learning and retinal photograph-derived CAC score is comparable to CT scan-measured CAC in 
predicting cardiovascular events, and improves on current risk stratification approaches for cardiovascular disease 
events. These data suggest retinal photograph-based deep learning has the potential to be used as an alternative 
measure of CAC, especially in low-resource settings.
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Technology, South Korea; Agency for Science, Technology, and Research; and National Medical Research Council, 
Singapore.
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Introduction
Cardiovascular disease is the leading cause of death 
worldwide.1 Coronary artery calcium (CAC) is a 
preclinical marker of atherosclerosis and is strongly 
associated with risk of clinical cardiovascular disease.2 
Measurement of CAC scores has increasingly been 
used for stratification of cardiovascular disease risk, in 
conjunction with clinical risk prediction models in 
international guidelines.3,4 The American College of 
Cardiology/American Heart Association (ACC/AHA) 
guidelines3,4 recommend the use of the Pooled Cohort 
Equation (PCE) to stratify people at risk of cardiovas­
cular disease and determine who should be given 
statin therapy. However, for patients classified in 
the intermediate­risk group based on the PCE, the 
clinician–patient risk discussion can include risk­
enhancing factors (eg, family history or CAC score). 
CAC score has been recommended as an additional test 
to refine risk estimates and improve selection for statin 
treatment.3,4 However, current measurement of CAC 
scores requires ready access to CT scans, which carries 
radiation risk.
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Retinal photographs provide information about human 
vasculature and insights into cardiovascular health.5 
Large population studies have shown that overt retinal 
vascular damage (eg, signs of retinopathy such as 
microaneurysms and retinal haemorrhages) and more 
subtle changes (eg, retinal arteriolar narrowing) are 
markers of subclinical cardiovascular disease (eg, carotid 
artery stenosis), and can predict major cardiovascular 
disease events and mortality.6–10 The recent application of 
artificial intelligence through deep­learning algorithms 
has suggested that retinal photographs can provide 
estimates on traditional cardiovascular disease risk 
factors, such as age, sex, and blood pressure,11,12 and can 
predict cardiovascular disease events with similar 
accuracy to a traditional cardiovascular disease risk 
calculator.12
We have extended this concept and hypothesise that 
retinal photograph­based deep learning can also predict 
CAC score, and this retinal­predicted score can also be 
used as a risk stratification tool for cardiovascular 
events. This hypothesis is relevant given that CAC is 
recommended3,4 as an additional test to help clinicians to 
better determine statin indication. Here, we developed a 
deep­learning algorithm to predict the probability of the 
presence of CAC based on retinal photographs (termed 
the deep­learning retinal CAC score, RetiCAC). Secondly, 
based on the RetiCAC, we proposed a new simplified 
cardiovascular disease risk stratification sys tem and 
validated its performance in data from three longitudinal 
studies from South Korea, Singapore, and the UK 
Biobank. Lastly, in the UK Biobank, we assessed whether 
RetiCAC could be used for cardiovascular disease risk 
discrimination similar to cardiac CT mea sured CAC, 
in line with current ACC/AHA guidelines, specifically 
among people in the PCE borderline­risk and inter­
mediate­risk groups.
Methods
Study design and population
We used clinical data and retinal photographs from five 
independent datasets or studies, including two datasets 
from two health­screening centres in South Korea; 
Cardiovascular and Metabolic Disease Etiology Research 
Center­High Risk (CMERC­HI), a prospective clinical 
cohort in South Korea; the Singapore Epidemiology of 
Eye Diseases (SEED) study, a prospective population­
based cohort in Singapore; and the UK Biobank, a 
prospective population­based cohort in the UK.
First, we extracted data from individuals who visited the 
health­screening centre affiliated with Severance Hospital, 
South Korea (screening centre 1; developmental and 
internal test set). We then extracted data from individuals 
who visited a health­screening centre affiliated with the 
Philip Medical Centre, South Korea (screening centre 2; 
external test set 1). For comparison between the RetiCAC 
and CAC score for risk stratification in clinical settings, 
we used clinical data from a longitudinal study, the 
CMERC­HI cohort (ClinicalTrials.gov, NCT02003781),13 
which targeted patients with a high cardiovascular disease 
risk (external test set 2). All examinations, including 
cardiac CT scans and retinal photography, were done on 
the same visit day in datasets from South Korea. In 
Research in context
Evidence before this study
Current guidelines such as the American College of Cardiology/
American Heart Association guideline use the Pooled Cohort 
Equation (PCE) to stratify people at risk of cardiovascular 
disease to determine commencement of statin therapy. For the 
intermediate-risk group, guidelines recommend measuring 
coronary artery calcium (CAC) to assist in the decision of statin 
therapy. We derived a deep learning-based CAC score predicted 
from retinal photographs (RetiCAC) and used this new RetiCAC 
score for cardiovascular risk stratification. Our search strategy 
consisted of studies that applied deep learning on retinal 
photographs for the prediction of cardiovascular events as of 
Sept 13, 2020. We combined the search terms artificial 
intelligence (“deep learning” or “machine learning”), retinal 
image (“fundus” or “retina”), and “coronary artery calcium”. 
We found only one study using deep learning to predict high 
CAC scores based on retinal photographs, but without 
demonstration of external validation.
Added value of this study
We developed RetiCAC to predict the presence of CT scan-
measured CAC. Based on RetiCAC, a new three-tier 
cardiovascular disease risk stratification system was developed, 
which showed comparable performance as current CT scan, 
and incremental prognostic performance over PCE in 
borderline-risk and intermediate-risk groups. The value added 
by this work lies in the demonstration of a retinal photograph-
based deep learning algorithm in predicting future major 
health events (ie, cardiovascular disease events and mortality) 
with external validation. To our knowledge, this is also the first 
study that compared the performance of a retinal photograph-
based deep learning algorithm with established clinical 
guideline standard, in predicting major cardiovascular events.
Implications of all the available evidence
With deep learning, retinal photographs can provide an 
estimate of CAC score, and could be used as a surrogate 
marker for cardiovascular risk stratification, which was 
compatible with cardiac CT scan in predicting cardiovascular 
disease events. Taken together, our findings suggest that 
retinal photography may be adopted as a more cost-effective 
method as compared with cardiac CT and non-radiation 
imaging modality for cardiovascular risk stratification.
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addition, we included the SEED cohort to determine the 
association between the RetiCAC score and incidence 
of cardiovascular disease events in an Asian general 
population comprising Chinese, Malay, and Indian 
people.14 Lastly, we used the UK Biobank data to evaluate 
the added value of our proposed RetiCAC score on the 
PCE3,4 in cardiovascular disease risk stratification.
Detailed information on the retinal cameras, CT 
scanning system, and measurements of clinical out­
comes used is provided in the appendix (pp 1–2). The 
numbers of patients excluded and included from the 
study populations are shown in the appendix (pp 3–4, 9). 
We included all participants to maximise the number of 
pairs of retinal photographs and cardiac CT scans for 
deep­learning model development. We then excluded 
missing data in four well established risk factors 
(smoking, hypertension, diabetes, and dyslipidaemia) in 
screening centre 1 for model evaluation (denoted as 
subset). In the UK Biobank, participants who were taking 
statins,15 and had cardio vascular disease at baseline were 
excluded.
This study was approved by the institutional review 
board of Severance Hospital, Yonsei University, Seoul, 
South Korea (4­2013­0581, 4­2018­0262, 4­2019­1259), and 
adhered to the tenets of the Declaration of Helsinki. 
Written, informed consent was obtained from the 
participants in the clinical cohort study and population­
based cohort studies.
Definition of the presence of CAC
We defined a CAC score of zero as absence of CAC, and 
more than zero as presence of CAC. The selection of this 
cutoff was supported by a series of studies that found a 
low cardiovascular disease risk among individuals with 
a CAC score of zero.16,17
Deep-learning algorithm for predicting the presence of 
CAC
Details regarding model development and visualisation 
techniques (ie, saliency maps) are provided in the 
appendix (pp 5–6). In model development, CAC was the 
main outcome as a binary variable, and the model inputs 
comprised of retinal photographs. We developed a deep­
learning algorithm using retinal photographs to predict 
the probability of the presence of CAC (ie, CAC scores >0), 
which we referred to as the RetiCAC score. To generate 
the saliency maps, we used guided backpropagation,18 and 
aggregated analysis was done.
Definition of cardiovascular disease events
In SEED, incident cardiovascular disease events were 
obtained by linking with Singapore’s National Registry 
of Disease Office.19 In the UK Biobank, we used 
hospitalisation and mortality data provided by the 
National Health Service (NHS) registers.20 In both SEED 
and UK Biobank, the primary outcome was incident 
fatal cardiovascular disease events, defined based on 
the European Systematic COronary Risk Evaluation 
(SCORE) clinical guidelines21 (International Classifica­
tion of Diseases [ICD]­10 codes, I10–15, I44–51, I20–25, 
and I61–73; hereafter SCORE cardiovascular disease 
events).20,22 The secondary outcome was incident 
athero sclerotic cardiovascular disease (ASCVD) events, 
defined in accordance with the ACC/AHA guidelines3 
(hereafter, referred to as ACC/AHA ASCVD events) 
including fatal ASCVD events (ICD­10 codes I20–25, 
I60–64) and non­fatal ASCVD events (hospitalisation 
due to ICD­10 codes I21, I22, I60–64).20
In CMERC­HI, we defined cardiovascular disease 
events as any of incident cardiovascular disease including 
heart failure, stroke, myocardial infarction, or all­cause 
mortality (detailed definitions can be found in the 
appendix p 7). In CMERC­HI, other­cause mortality was 
also included in the evaluated outcome, because the 
non­fatal and fatal cardiovascular disease events were 
relatively few due to a short follow­up of 5 years.
New cardiovascular disease risk stratification system
The RetiCAC score was defined based on a probability 
score derived from our deep­learning algorithm of 
binary classification (absence vs presence of CAC). The 
probability scores ranged from zero to one, with a high 
value indicating a high probability of the presence of 
CAC. The distribution of the estimated RetiCAC scores 
is provided in the appendix (p 10). We proposed a 
new cardiovascular disease risk stratification system 
based on the tertiles of RetiCAC scores in CMERC­HI 
(1st tertile ≥0 to <0∙3093, low risk; 2nd tertile 
≥0∙3093 to ≤0∙4074, moderate risk; and 3rd tertile 
>0∙4074 to ≤1, high risk). We then compared the 
performance of our proposed RetiCAC system in 
predicting cardiovascular disease events to that based 
on three­strata risk stratification according to cardiac 
CT­measured CAC scores (0, >0–100, and >100).3 We also 
used these proposed cutoff values to further stratify the 
cardiovascular disease risk in the SEED and UK Biobank 
participants.
Calculation of the PCE in the UK Biobank
We estimated cardiovascular disease risk according to 
the PCE, following the ACC/AHA guidelines.3 In our 
primary analysis, we included only White participants 
in the UK Biobank, and estimated their 10­year ASCVD 
risk according to the PCE, because most (92%) of the 
UK Biobank participants were White and the equation 
was only validated for non­Hispanic Black people and 
non­Hispanic White people.3 The distribution of the PCE 
estimates is provided in the appendix (p 10).
Statistical analysis
Analyses were done using p less than 0∙05 as the 
significance level, and using Python 3.7 for deep­
learning algorithm development, Stata/MP version 14.0 
for survival analysis, and R version 3.4.4 for estimation of 
See Online for appendix
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net reclassification index (NRI) using the R package 
survIDINRI.23
To evaluate the performance of the deep­learning 
algorithm, we calculated the area under the receiver 
operating characteristic curve (AUC) in the prediction of 
the presence of CAC.24 The AUC of RetiCAC score was 
compared with that of age using Delong methods.25 In 
addition, we used continuous NRI23 to compare the 
performance of the multiparameter models with and 
without RetiCAC. To obtain the 95% CIs, we used the 
non­parametric bootstrap procedure with 2000 samples.
In CMERC­HI, each patient was followed up to 5 years 
from the date of baseline visit to the last follow­up date of 
Dec 31, 2018, or the date of the cardiovascular disease 
events. Cumulative incidence of cardiovascular events 
was evaluated across the three groups (low, moderate, 
and high risk) defined by the RetiCAC scores and 
across three groups stratified according to the cardiac 
CT­measured CAC scores (0, >0–100, and >100) using the 
Kaplan­Meier method, and Cox proportional hazards 
model to estimate the hazard ratios (HRs). Trends in HRs 
and p value for trend were examined by fitting a linear 
model for the tertile categories.
In both SEED and the UK Biobank, cumulative 
incidence of cardiovascular disease events was evaluated 
across the three risk groups (low, moderate, and high risk) 
defined by the RetiCAC score using Cox pro portional 
hazard model. In SEED, hospitalisation and mortality data 
were available up to Dec 31, 2018, at the time of analysis 
and each participant was followed up to 14 years from the 
date of baseline visit. In the UK Biobank, hospitalisation 
and mortality data were available up to March 18, 2020, at 
the time of analysis and each participant was followed up 
to 10 years from the date of baseline visit. Risk­adjusted 
Subset from 
screening centre 1 
(internal test set)
Screening centre 2 




Participants 2536 8707 527 8551 47 679
Examinations 2795 9460 527 8551 47 679
Retinal photographs 5590 18 920 1054 17 102* 95 358
CAC
Median 0∙0 (0∙0–10∙0) 0∙0 (0∙0–2∙8) 16∙3 (0∙0–170∙6) NA NA
0 1873 (67∙0%) 6789 (71∙8%) 217 (41∙2%) NA NA
>0 922 (33∙0%) 2671 (28∙2%) 310 (58∙8%) NA NA
>100 286 (10∙2%) 709 (7∙5%) 165 (31∙3%) NA NA
Clinical biomarkers
Age, years 53∙6 (7∙0) 50∙3 (7∙5) 60∙0 (11∙7) 58∙1 (10∙2) 56∙6 (8∙2)
Sex
Female 802 (38∙0%) 2689 (36∙4%) 246 (46∙7%) 4472 (52∙3%) 27 012 (56∙7%)
Male 1734 (62∙0%) 6018 (63∙6%) 281 (53∙3%) 4079 (47∙7%) 20 667 (43∙3%)
Systolic blood pressure, mm Hg 123∙8 (14∙8) 119∙7 (13∙5) 131∙2 (15∙4) 139∙5 (21∙8) 139∙2 (19∙6)
Diastolic blood pressure, mm Hg 78∙4 (10∙8) 73∙0 (9∙6) 78∙6 (8∙7) 78∙6 (10∙5) 81∙5 (10∙6)
Fasting glucose, mg/dL 101∙4 (21∙9) 104∙0 (21∙9) 108∙8 (28∙3) 120∙6 (21∙0) 90∙9 (14∙0)
Body-mass index, kg/m² 24∙5 (3∙4) 24∙4 (3∙3) 25∙5 (3∙6) 25∙4 (4∙7) 26∙7 (4∙5)
Hypertension 572 (20∙5%) NA 453 (86∙0%) 5069 (59∙3%) 24 375 (51∙1%)
Diabetes 207 (7∙4%) NA 67 (12∙7%) 2389 (27∙9%) 691 (1∙4%)
Dyslipidaemia 196 (7∙0%) NA 264 (50∙1%) 3621 (42∙4%) 14 494 (30∙4%)
Current smoker 1264 (45∙2%) NA 234 (44∙4%) 1354 (15∙9%) 4058 (8∙5%)
Cardiovascular disease events
Total events NA NA 33 (6∙3%) NA NA
Median follow-up, years NA NA 4∙1 (3∙8–4∙5) NA NA
SCORE cardiovascular disease 
events†
NA NA NA 310 (3∙6%) 337 (0∙7%)
Median follow-up, years NA NA NA 10∙3 (8∙7–12∙7) 9∙9 (9∙8–10∙1)
 ACC/AHA ASCVD events‡ NA NA NA 992 (11∙6%) 1184 (2∙5%)
Median follow-up, years NA NA NA 9∙9 (8∙3–11∙5) 9∙9 (9∙7–10∙0)
Data are n, n (%), mean (SD), or median (IQR). CMERC-HI=Cardiovascular and Metabolic Disease Etiology Research Center-High Risk Cohort. SEED=Singapore 
Epidemiology of Eye Diseases. CAC=coronary artery calcium. NA=not available. SCORE=Systematic COronary Risk Evaluation. ACC/AHA=American College of Cardiology/
American Heart Association. ASCVD=atherosclerotic cardiovascular disease. *Estimated based on average number of photographs per person. †Primary outcome. 
‡Secondary outcome.
Table 1: Characteristics of the study population 
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models included age, sex, hypertension, dyslipidaemia, 
diabetes, and smoking as covariates.
The incremental prognostic value of the RetiCAC over 
the PCE in the prediction of cardiovascular disease 
events was assessed using the Kaplan­Meier method, 
Harrell’s C statistic,25 and continuous NRI23 in the 
borderline­risk and intermediate­risk groups in the UK 
Biobank. Cumulative incidence of cardiovascular disease 
events was evaluated across four risk groups stratified by 
the PCE (<5% [low risk]; 5% to <7∙5% [borderline risk]; 
≥7∙5% to <20% [intermediate risk]; and ≥20% [high 
risk]), and the three groups (low, moderate, and high 
risk) according to the RetiCAC score.
For sensitivity analyses, in the UK Biobank, to account 
for the possibility of reverse causality, we did a landmark 
analysis in which we excluded participants who expe­
rienced events within the first 2 years of follow­up. We 
then repeated our analysis including individuals under 
statin treatment. In addition, we repeated our analysis 
including all participants (Black, Chinese, mixed or other 
ethnic backgrounds, south Asian, and White participants).
Role of the funding source
The funders had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report.
Results
The clinical characteristics of study participants are 
provided in table 1. In CMERC­HI, the median baseline 
CAC score was 16∙3 (IQR 0∙0–170∙6) and 33 (6∙3%) of 
the 527 participants had cardiovascular disease events 
during the 5­year follow­up. In SEED, there were 
310 (3∙6%) SCORE cardiovascular disease events 
among 8551 participants. In the UK Biobank, there 
were 337 (0∙7%) SCORE cardiovascular disease events 
among 47 679 participants. The characteristics of the 
entire dataset of screening centre 1 for development of 
deep­learning algorithm (appendix p 17) and those of 
the excluded participants (appendix p 18) are provided 
in the appendix.
Using the internal test set, the Spearman’s rank cor­
relation coefficient between RetiCAC and CT­measured 
CAC scores was 0∙47 (p<0∙0001, data not shown). The 
performance of RetiCAC in predicting presence of CAC is 
detailed in table 2. The RetiCAC score model showed 
superior performance with an AUC of 0∙742 (95% CI 
0∙732–0∙753), compared with single­parameter models, 
such as age (0∙705, 0∙693–0∙716) and glucose (0∙637, 
0∙625–0∙650) in the external test set 1. However, after 
adding RetiCAC to the multiparameter model, there was 
little or no improvement in AUCs (p>0·05), and the 
Internal test set External test set 1 External test set 2
Single-parameter model
LDL cholesterol 0∙496 (0∙472–0∙519) 0∙516 (0∙503–0∙530) 0∙597 (0∙547–0∙646)
Total cholesterol 0∙513 (0∙490–0∙537) 0∙510 (0∙497–0∙523) 0∙592 (0∙543–0∙642)
Dyslipidaemia 0∙525 (0∙514–0∙536) NA 0∙562 (0∙518–0∙605)
Diabetes 0∙540 (0∙528–0∙552) NA 0∙553 (0∙527–0∙580)
Triglyceride 0∙562 (0∙539–0∙584) 0∙595 (0∙582–0∙607) 0∙512 (0∙462–0∙563)
HDL cholesterol 0∙566 (0∙544–0∙588) 0∙613 (0∙600–0∙625) 0∙555 (0∙506–0∙605)
Diastolic blood pressure 0∙575 (0∙553–0∙598) 0∙582 (0∙569–0∙594) 0∙498 (0∙447–0∙548)
Systolic blood pressure 0∙577 (0∙555–0∙599) 0∙613 (0∙600–0∙625) 0∙588 (0∙539–0∙637)
Hypertension 0∙589 (0∙571–0∙606) NA 0∙498 (0∙468–0∙528)
Current smoker 0∙586 (0∙566–0∙605) NA 0∙533 (0∙490–0∙576)
Body-mass index 0∙602 (0∙581–0∙624) 0∙607 (0∙595–0∙619) 0∙543 (0∙492–0∙594)
Sex 0∙621 (0∙604–0∙639) 0∙621 (0∙611–0∙630) 0∙542 (0∙499–0∙585)
Glucose 0∙628 (0∙606–0∙650) 0∙637 (0∙625–0∙650) 0∙563 (0∙514–0∙612)
Age 0∙690 (0∙669–0∙710) 0∙705 (0∙693–0∙716) 0∙705 (0∙660–0∙749)
RetiCAC score* 0∙731 (0∙712–0∙751) 0∙742 (0∙732–0∙753) 0∙729 (0∙685–0∙773)
Multiparameter model
All risk factors† 0∙769 (0∙751–0∙787) 0∙782 (0∙772–0∙791) 0∙725 (0∙681–0∙769)
All risk factors plus RetiCAC 0∙769 (0∙751–0∙787) 0∙784 (0∙775–0∙794) 0∙749 (0∙707–0∙792)
NRI (95% CI) 0∙227 (0∙134–0∙311) 0∙267 (0∙219–0∙310) 0∙321 (0∙132–0∙441)
NRI positive, NRI negative 0∙082, 0∙145 0∙114, 0∙153 0∙058, 0∙263
Data are AUC (95% CI), unless stated otherwise. The presence of CAC defined as a score of more than zero. NRI in individuals with abnormal CAC score (NRI positive) and 
individuals with zero CAC score (NRI negative) were provided (all p values were <0∙0001). RetiCAC=deep-learning retinal coronary artery calcium. CAC=coronary artery 
calcium. AUC=area under the receiver operating characteristic curve. NA=data not available. NRI=net reclassification index. *Significant difference between age and RetiCAC 
models in internal test set and external test set 1 (p<0∙0001), and non-significant difference in external test set 2 (p=0∙249) based on DeLong’s method. †All risk factors 
model included the 14 single parameters listed above. Non-significant difference between all risk factors and all risk factors plus RetiCAC models in internal test set and 
external test set 1 (p>0∙05), and significant difference in external test set 2 (p=0∙034) based on DeLong’s method.
Table 2: Performances of deep-learning RetiCAC score versus traditional clinical parameters in predicting individuals with the presence of CAC
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continuous NRI was 0∙267 (95% CI, 0∙219–0∙310) in 
external test set 1. Similar findings were observed in 
external test set 2. ROC and precision­recall curves 
(appendix p 11) and confusion matrices (appendix p 19) 
are presented in the appendix.
The saliency maps show that the deep­learning 
algorithm used features of blood vessels around the optic 
disc or arcade blood vessels (appendix p 12). Aggregated 
saliency maps indicated that the highlighted area along 
the arcade vessels was more prominent in images of 
higher scores (appendix p 13).
The clinical characteristics of the CMERC­HI partici­
pants by the tertile groups of RetiCAC score are 
detailed in the appendix (p 20). Median CAC scores 
were highest in the highest tertile group. The 
participants in the lowest tertile group had fewer 
cardiovascular disease events (n=5, 2∙8%) than those 
in the highest tertile group (n=20, 11∙4%; p=0∙002). 
Similar findings were observed in the SEED study and 
the UK Biobank, where the participants in the low risk 
of RetiCAC group had fewer cardiovascular disease 
events (appendix pp 21–22).
Kaplan­Meier curves in CMERC­HI are given in 
figure 1. During the 5­year follow­up (median 4∙1 years, 
IQR 3∙8–4∙5), 2164∙4 person­years were examined. 
Kaplan­Meier curves show distinct cardiovascular 
disease risk stratification based on the tertiles of the 
RetiCAC scores. Similar to the current CT­measured 
CAC stratification system, the HRs of cardiovascular 
disease events showed a dose­response association 
across the three risk strata (risk­adjusted HR trend 2∙02, 
95% CI 1∙18–3∙46; table 3). Overall, in CMERC­HI, the 
proposed new stratification system based on RetiCAC 
score (C statistic 0∙71, 95% CI 0∙59–0∙82) showed 
comparable performance in predicting cardio vascular 
disease events compared with conventional CT­measured 
CAC score (C statistic 0∙71, 0∙61–0∙80; p=0∙963; 
table 3).
In SEED and the UK Biobank, based on RetiCAC 
score, the risk­adjusted HRs for incident SCORE 
cardiovascular disease events showed a dose­response 
association across the three strata of RetiCAC, with 
HR trends of 1∙33 (95% CI 1∙04–1∙71), and 1∙21 
(1∙05–1∙40), respectively (table 3). Improvement in 
predictive performance with the addition of RetiCAC to 
the cardiovascular disease risk models is provided in 
the appendix (p 23). Furthermore, because of the 
potential correlations between RetiCAC and other 
cardiovascular disease risk factors, we did a sensitivity 
analysis by using the proportion of RetiCAC uncor­
related from age, sex, and other clinical risk factors to 
predict cardiovascular disease events (appendix p 8), 
and the findings were similar.
The Kaplan­Meier analysis of cardiovascular disease 
events in the UK Biobank by the four groups of the PCE 
and three strata of RetiCAC are given in figure 2. In 
the borderline­risk group, the three strata of RetiCAC 
could further stratify the risk of SCORE cardiovascular 
disease events (HR trend 1∙62, 95% CI 1∙04–2∙54, 
across the three RetiCAC strata). Similarly, in the 
Figure 1: Kaplan-Meier estimates for cumulative incidence of cardiovascular events in the CMERC-HI cohort
(A) Cardiovascular disease event by RetiCAC score. (B) Cardiovascular disease event by CAC score. Cumulative event rates of cardiovascular disease events including 
incident heart failure, stroke, myocardial infarction, and all-cause mortality using the new three-strata risk stratification system of deep learning-based RetiCAC 
score (A), and CAC stratification (0, >0–100, and >100) (B) in the clinical cohort of CMERC-HI (n=527). CMERC-HI=Cardiovascular and Metabolic Disease Etiology 
Research Center-High Risk. CAC=coronary artery calcium. RetiCAC=deep-learning retinal coronary artery calcium.
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intermediate­risk group, the three strata of RetiCAC 
also showed stratification of SCORE cardiovascular 
disease events (1∙28, 1∙07–1∙54).
We also tested the incremental value of the RetiCAC 
score to PCE in predicting incident cardiovascular dis ease 
events, among the borderline­risk and intermediate­risk 
groups (table 4). By adding RetiCAC score to PCE, 
C statistics increased by 0∙031 (95% CI 0∙010–0∙051) and 
the continuous NRI was 0∙261 (95% CI 0∙124–0∙364) 
for prediction of SCORE cardiovascular disease events. 
Similarly, C statistics increased by 0∙014 (95% CI 
0∙003–0∙025) and the continuous NRI was 0∙222 (95% CI 
Cardiovascular 
disease events/n
Person-years Incidence* Age-adjusted and sex-adjusted 
model
Risk-adjusted model†
HR (95% CI) p value HR (95% CI) p value
CMERC-HI dataset
CAC score
0 6/217 895∙2 0∙7 1 (ref) NA 1 (ref) NA
>0–100 9/145 604∙5 1∙5 2∙35 (0∙80–6∙89) 0∙159 2∙19 (0∙74–6∙50) 0∙159
>100 18/165 664∙7 2∙7 4∙18 (1∙53–11∙38) 0∙005 3∙34 (1∙20–9∙36) 0∙021
HR trend NA NA NA 1∙51 (1∙14–2∙02) 0∙005‡ 1∙40 (1∙04–1∙88) 0∙024‡
C statistic NA NA NA 0∙67 (0∙57–0∙76) NA 0∙71 (0∙61–0∙80) NA
RetiCAC score
Low 5/176 721∙7 0∙7 1 (ref) NA 1 (ref) NA
Moderate 8/176 727∙2 1∙1 1∙90 (0∙58–6∙77) 0∙274 1∙71 (0∙49–5∙98) 0∙399
High 20/175 715∙6 2∙8 5∙43 (1∙63–18∙07) 0∙006 4∙10 (1∙22–13∙77) 0∙023
HR trend NA NA NA 2∙37 (1∙37–4∙09) 0∙002‡ 2∙02 (1∙18–3∙46) 0∙009‡
C statistic NA NA NA 0∙68 (0∙58–0∙79) NA 0∙71 (0∙59–0∙82) NA
SEED dataset
RetiCAC score for SCORE cardiovascular events
Low 29/2327 24 547∙2 0∙1 1 (ref) NA 1 (ref) NA
Moderate 52/2966 30 944∙4 0∙2 1∙26 (0∙79–2∙01) 0∙338 1∙04 (0∙65–1∙67) 0∙856
High 229/3258 31 594∙7 0∙7 2∙28 (1∙38–3∙77) 0∙001 1∙63 (0∙98–2∙69) 0∙058
HR trend NA NA NA 1∙57 (1∙22–2∙01) <0∙001‡ 1∙33 (1∙04–1∙71) 0∙023‡ 
C statistic NA NA NA 0∙77 (0∙75–0∙80) NA 0∙81 (0∙79–0∙83) NA
RetiCAC score for ACC/AHA ASCVD events
Low 152/2327 23 862∙6 0∙6 1 (ref) NA 1 (ref) NA
Moderate 240/2966 29 988∙3 0∙8 1∙34 (1∙09–1∙66) 0∙007 1∙15 (0∙93–1∙42) 0∙201
High 600/3258 29 675∙9 2∙0 2∙07 (1∙61–2∙65) <0∙001 1∙53 (1∙19–1∙96) <0∙001
HR trend NA NA NA 1∙45 (1∙28–1∙64) <0∙001‡ 1∙25 (1∙10–1∙41) <0∙001‡
C statistic NA NA NA 0∙71 (0∙70–0∙73) NA 0∙76 (0∙74–0∙77) NA
UK Biobank dataset
RetiCAC score for SCORE cardiovascular disease events
Low 76/22 431 216 303∙7 0∙4 1 (ref) NA 1 (ref) NA
Moderate 140/14 624 136 340∙1 1∙0 1∙60 (1∙20–2∙13) 0∙001 1∙51 (1∙14–2∙02) 0∙005
High 121/10 624 95 520∙9 1∙3 1∙64 (1∙21–2∙22) 0∙001 1∙54 (1∙14–2∙08) 0∙005
HR trend NA NA NA 1∙25 (1∙08–1∙44) 0∙002‡ 1∙21 (1∙05–1∙40) 0∙008‡
C statistic NA NA NA 0∙77 (0∙75–0∙79) NA 0∙80 (0∙77–0∙82) NA
RetiCAC score for ACC/AHA ASCVD events
Low 360/22 431 213 039∙3 1∙7 1 (ref) NA 1 (ref) NA
Moderate 419/14 624 133 693∙0 3∙1 1∙18 (1∙02–1∙37) 0∙025 1∙13 (0∙98–1∙31) 0∙097
High 405/10 624 93 326∙6 4∙3 1∙41 (1∙21–1∙64) <0∙0001 1∙35 (1∙16–1∙57) 0∙0001
HR trend NA NA NA 1∙19 (1∙10–1∙28) <0∙0001‡ 1∙16 (1∙08–1∙25) 0∙0001‡
C statistic NA NA NA 0∙71 (0∙70–0∙73) NA 0∙74 (0∙73–0∙76) NA
The C statistic values in the same row were from different models: age-adjusted and sex-adjusted model and all risk factors-adjusted model. n=number at risk. HR=hazard 
ratio. CMERC-HI=Cardiovascular and Metabolic Disease Etiology Research Center-High Risk Cohort. CAC=coronary artery calcium. NA=not applicable. RetiCAC=deep-
learning retinal coronary artery calcium. SEED=Singapore Epidemiology of Eye Diseases. SCORE=Systematic COronary Risk Evaluation. ACC/AHA=American College of 
Cardiology/American Heart Association. ASCVD=atherosclerotic cardiovascular disease. *Incidence per 100 person-years for CMERC-HI and SEED, per 1000 person-years for 
the UK Biobank. †Risk-adjusted controlling for age, sex, hypertension, dyslipidaemia, diabetes, and smoking. ‡p value for trend.
Table 3: Risk of cardiovascular events by the deep-learning RetiCAC score and cardiac CT-measured CAC score
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0∙148–0∙289) for prediction of ACC/AHA ASCVD events 
(table 4).
In the additional landmark analysis, we observed 
similar findings in risk stratification (appendix p 14). 
Sensitivity analyses that included individuals on statin 
therapy and all ethnic groups also showed results 
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Discussion
In this study, we developed a deep­learning algorithm 
(RetiCAC) using retinal photographs to predict the 
presence of CAC. The RetiCAC scores showed superior 
performance compared with a single clinical parameter, 
such as age, glucose, or smoking status, in predicting the 
presence of CAC. We then proposed a novel three­tier 
cardiovascular disease risk stratification system based on 
RetiCAC score, which was comparable to the current 
three­tier CT­scan measured CAC scores in predicting 
cardiovascular disease events in a South Korean clinical 
cohort. The RetiCAC score was also able to stratify 
cardiovascular disease risk in an Asian general population 
comprising multiple ethnicities (Chinese, Malay, and 
Indian) in Singapore. Moreover, in a large British cohort of 
the UK Biobank, we showed RetiCAC could further stratify 
the cardiovascular disease risk in individuals classified 
by PCE as borderline­risk and intermediate­risk groups.
The novelty of the present study is further extending 
the previous work by Poplin and colleagues12 to cardiac 
CT­measured CAC and its value in predicting future 
cardiovascular disease events and mortality. Recently, a 
deep­learning algorithm to predict abnormal CAC from 
retinal photographs was reported,26 but the algorithm 
was not validated in independent datasets, and its ability 
to predict future cardiovascular disease events was not 
evaluated.
First, in the present study, we found that retina alone 
provided more information and signals for CAC 
prediction than any single clinical parameter, such as age 
or total cholesterol. The association among chronological 
age, CAC, and systemic atherosclerotic burden has been 
well established;27 age and CAC might be viewed as a 
surrogate marker of atherosclerotic plaque burden, and 
age is one of the strongest predicting factors for CAC.28 
Nonetheless, our study confirms that the RetiCAC score 
is better than age and any other clinical parameters, for 
predicting the presence of CAC.
Second, our study confirmed the known links between 
retinal vascular damage (eg, retinal arteriolar narrowing, 
or retinopathy) and cardiovascular disease risk.5 In 
saliency maps, retinal signs such as haemorrhage or 
cotton wool spots, which are known to be associated 
with cardiovascular disease risk,5 were highlighted, 
implying that the algorithm accurately detected the 
clinically relevant retinal features to predict the presence 
of CAC.
Third, our study proposed that RetiCAC, a novel 
cardiovascular disease risk stratification system using 
relatively simple and non­radiation retinal photographs, 
was comparable to conventional CT­scan­measured 
CAC scores in predicting cardiovascular disease events. 
Moreover, using a large cohort, we showed that the added 
value of the RetiCAC score in improving cardiovas­
cular disease risk stratification in borderline­risk and 
intermediate­risk groups in PCE in the UK Biobank. For 
example, after being further stratified based on RetiCAC 
score, the low­risk subgroup at intermediate risk from 
PCE and high­risk subgroup at borderline risk from PCE 
showed overlapped cumulative cardiovascular disease risk 
until 6­year follow­up (figure 2). This finding appears to be 
particularly useful in selecting patients for statin therapy 
if patients are undecided after clinician–patient risk 
discussion with consideration of risk enhancing factors. 
Although direct comparisons of NRI should be made with 
caution because definitions of the outcome and length of 
follow­up differ, the improvements by adding RetiCAC 
score to PCE in predicting cardiovascular disease events 
in the PCE borderline­risk and intermediate­risk groups 
(NRI of 22–26%) was somewhat lower to the previously 
reported improvement (NRI of 66%) by adding CAC to 
Framingham risk score in Yeboah and colleagues’ study 
using Multi­Ethnic Study of Atherosclerosis (MESA) 
cohort.29 However, this same group also reported NRI of 
12% when CAC was added to the calibrated PCE using 
the same dataset.30 Therefore, although the degree of 
improvement by RetiCAC in risk stratification was modest 
in this study, RetiCAC might still have a role for ASCVD 
risk assessment.
Figure 2: Kaplan-Meier estimates for cumulative incidence of cardiovascular 
events in the UK Biobank
Cumulative event rates of SCORE cardiovascular disease (primary outcome; 
A and C) and ACC/AHA ASCVD (secondary outcome; B and D) events stratified 
by the PCE (low-risk, borderline-risk, intermediate-risk, and high-risk groups; 
A and B) and the RetiCAC score (low-risk, moderate-risk, and high-risk groups) 
in PCE borderline-risk and intermediate-risk groups (C and D) in the UK 
Biobank (n=47 679). Incidence per 1000 person-years with HRs are provided. 
The three strata of RetiCAC could further stratify the risk of SCORE 
cardiovascular events with HR trend of 1∙62 (95% CI 1∙04–2∙54) in PCE 
borderline-risk group and with HR trend of 1∙28 (1∙07–1∙54) in PCE 
intermediate-risk group (C). The three strata of RetiCAC could further stratify 
the risk of AHA/ACC ASCVD events with HR trend of 1∙26 (1∙01–1∙58) in PCE 
borderline-risk group and 1∙18 (1∙07–1∙30) in PCE intermediate-risk group (D). 
PCE=Pooled Cohort Equation. RetiCAC=deep-learning retinal coronary artery 
calcium. SCORE=Systematic COronary Risk Evaluation. HR=hazard ratio. 
ACC/AHA=American College of Cardiology/American Heart Association. 
ASCVD=atherosclerotic cardiovascular disease. 
SCORE cardiovascular 
disease events (n=223)
p value ACC/AHA ASCVD 
events (n=804)
p value
RetiCAC 0∙576 (0∙542–0∙611) NA 0∙543 (0∙524–0∙562) NA
PCE 0∙595 (0∙572–0∙618) NA 0∙579 (0∙566–0∙592) NA
RetiCAC plus PCE 0∙626 (0∙595–0∙657) NA 0∙593 (0∙576–0∙610) NA
∆ RetiCAC plus PCE vs PCE* 0∙031 (0∙010–0∙051) 0∙0036 0∙014 (0∙003–0∙025) 0∙0133
NRI
Continuous NRI (95% CI) 0∙261 (0∙124–0∙364) <0∙0001 0∙222 (0∙148–0∙289) <0∙0001
NRI positive, NRI negative 0∙158, 0∙103 NA 0∙031, 0∙192 NA
Data are C statistic (95% CI), unless stated otherwise. N=22 077. The RetiCAC plus PCE model is a logistic model fit on 
the UK Biobank. NRI for RetiCAC plus PCE versus PCE models and NRI in events group (NRI positive) and non-events 
group (NRI negative) were provided. SCORE=Systematic COronary Risk Evaluation. ACC/AHA=American College of 
Cardiology/American Heart Association. ASCVD=atherosclerotic cardiovascular disease. RetiCAC=deep-learning retinal 
coronary artery calcium score. NA=not applicable. PCE=Pooled Cohort Equation. NRI=net reclassification index. 
*Difference in C statistics between the model including RetiCAC plus PCE versus PCE alone.
Table 4: Predictive performance with the addition of RetiCAC score to the PCE in the UK Biobank
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A strength of this study was the use of large­scale CT 
data, which enabled us to use CAC—one of the most well 
established biomarkers of cardiovascular disease—for 
the deep­learning model development from retina 
photographs. Additionally, the added value of our new 
deep­learning­based biomarker was shown over the up­
to­date clinical guideline (ie, PCE), using a representative 
European cohort with more than 10 years of follow­up.
However, our study had some limitations. First, 
RetiCAC, as a prognostic biomarker for cardiovascular 
disease, was validated in only South Korean participants, 
Singaporean (Chinese, Malay, and Indian) participants, 
and participants in the UK Biobank. In addition, 
sensitivity analysis including all ethnicities in the UK 
Biobank showed the RetiCAC as a biomarker for risk 
discrimination but meaningful analysis by detailed 
ethnicities was not possible due to small sample sizes. 
Therefore, further studies in other ethnicities and 
countries are needed. Second, there is a potential 
selection bias in our data because the training set was 
obtained from health screening centres and thus might 
not represent the general population. Third, the survival 
models that incorporate death and hospital inpatient data 
for the definition of incident cardiovascular disease 
might have introduced some misclassification in the 
SEED and UK Biobank due to the nature of administrative 
data. Fourth, in CMERC­HI, the cardiovascular disease 
outcomes were relatively rare for meaningful analysis 
due to a short follow­up period of 5 years. Therefore, we 
also included other­cause deaths as event outcomes. 
Fifth, further studies that include more CAC data are 
needed to test the performance changes for CAC 
prediction and directly compare cardiovascular disease 
risk prediction between CT­measured CAC score and 
RetiCAC. In addition, because of the scarcity of cohort 
data with well defined cardiovascular disease events 
and retinal photographs, we applied the US­based risk 
calculator for the UK population while SCORE is typically 
the risk calculator for the UK population. Therefore, 
further studies based on the US population such as the 
MESA study might provide more convincing evidence. 
Lastly, studies with enough outcomes data are needed 
to train the deep­learning algorithm to predict cardio­
vascular disease events directly from retinal photographs. 
There could be additional insights and improvements 
through training on ASCVD outcomes,
We developed a deep­learning algorithm to predict 
presence of CAC from retinal photographs. RetiCAC 
predicted the presence of CAC better than other risk 
factors alone. Based on this finding, we proposed a 
new simple cardiovascular disease risk stratification 
system (RetiCAC score in tertiles) with comparable 
performance with the conventional CAC measured by 
cardiac CT scan. Furthermore, using the RetiCAC score 
together with PCE enhances the ability to further 
stratify cardiovascular disease risk in general popula­
tions. Thus, retinal photo graphy could potentially be 
adopted as a relatively simple and non­radiation 
imaging modality for cardio vascular disease risk 
classification.
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